Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Danaher (DHR) Q4 Earnings & Revenues Top Estimates, Up Y/Y

Published 01/29/2018, 10:28 PM
Updated 07/09/2023, 06:31 AM

Danaher Corporation (NYSE:DHR) delivered adjusted earnings of $1.19 a share in fourth-quarter 2017, beating the Zacks Consensus Estimate of $1.16 by 2.6%. Further, adjusted earnings increased 13.3% on a year-over-year basis.

The upside in the company’s bottom-line can largely be attributed to Danaher Business System (“DBS”) that focuses on three critical areas — quality, delivery, and cost & innovation. Moreover, a decent top-line performance led to double-digit adjusted earnings per share growth, solid margin expansion as well as strong cash flow during the quarter.

For full-year 2017, Danaher’s adjusted earnings came in at $3.50 per share, up 13.5% on a year-over-year basis.

Inside The Headlines

The company reported total sales of $5,085.7 million, reflecting an increase of 10.9% year over year. Moreover, the sales figure surpassed the Zacks Consensus Estimate of $4,972 million. Further, core businesses grew 5.5% year over year, partially offset by adverse effect of currency exchange rates fluctuations.

For 2017, Danaher reported net sales of $ 18,329.7 million, up 8.6% on a year-over-year basis.

Danaher Corporation Price, Consensus and EPS Surprise

Danaher Corporation Price, Consensus and EPS Surprise | Danaher Corporation Quote

Life Sciences revenues rose 11.8% year over year to $1,625.1 million. Operating margin for the quarter increased 320 basis points (bps) to 20.0%. Impressive growth in operating margin came primarily on the back of increased sales volumes. Revenues at the Diagnostics segment recorded an increase of 13.4% year over year to $ 1,623.9 million. Moreover, operating margin at the segment increased 690 bps year over year to 19.5%.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Revenues at Dental were up 2.6% year over year to $758.8 million. However, operating margin decreased 230 bps to 13.1%. The Environmental & Applied Solutions segment witnessed revenue growth of 12.4% year over year to $1,077.9 million. However, operating margin fell 90 bps to 23.1% on a year-over-year basis.

On a year-over-year basis, operating profit margin improved 270 bps to 18.6%.

Liquidity

As of Dec 31, 2017, Danaher had cash and equivalents of $630.3 million compared with the year-ago figure of $963.7 million.

Outlook

Concurrent with the earnings release, Danaher provided guidance for first-quarter 2018. The company projects adjusted earnings per share in the range of 90-93 cents.

Moreover, Danaher provided full-year 2018 adjusted earnings guidance. The company currently expects adjusted net earnings per share in the band of $4.25-$4.35.

Our Take

2017 was a spectacular year for Danaher, marked by solid margin improvement, continued growth investment as well as strong performance at its recently acquired larger businesses. Also, the company expects core growth rate to accelerate going forward, in light of improving order trends and recent acquisitions like Cepheid and Phenomenex forming a part of core revenues.

Moreover, the company has successfully repositioned itself as a healthcare company, broadening presence in the healthcare and dental markets. This is expected to benefit from the rise in aging population and increased spending on healthcare and fitness.

Danaher currently carries a Zacks Rank #3 (Hold).

Stocks to Consider

Some stocks worth considering in the same space include Hitachi Ltd. (OTC:HTHIY) , Leucadia National Corporation (NYSE:LUK) and Raven Industries, Inc. (NASDAQ:RAVN) . While Hitachi sports a Zacks Rank #1 (Strong Buy), Leucadia National and Raven Industries carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Hitachi has an excellent earnings surprise history, beating estimates in the trailing four quarters with an average beat of 85.8%.

Leucadia National has a modest earnings surprise history over the trailing four quarters, having beaten estimates thrice. It has delivered an average beat of 21.2%.

Raven Industries has posted earnings beat thrice in the trailing four quarters. It boasts an average surprise of 25.8%.

Don’t Even Think About Buying Bitcoin Until You Read This

The most popular cryptocurrency skyrocketed last year, giving some investors the chance to bank 20X returns or even more. Those gains, however, came with serious volatility and risk. Bitcoin sank 25% or more 3 times in 2017.

Zacks has just released a new Special Report to help readers capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly.

See 4 crypto-related stocks now >>



Danaher Corporation (DHR): Free Stock Analysis Report

Leucadia National Corporation (LUK): Free Stock Analysis Report

Raven Industries, Inc. (RAVN): Free Stock Analysis Report

Hitachi Ltd. (HTHIY): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.